WASHINGTON, D.C. — As President Obama prepared Monday for his speech to Congress on health care reform, some details leaked out about fees and coverage limits under a proposal being floated by the chairman of the Senate Finance Committee,  according to the New York Times.
The proposal from Sen. Max Baucus, a Montana Democrat, would impose new fees on some sectors of the health care industry — but none on individuals — to offset initial costs estimated at $880 billion over 10 years, according to officials familiar with the proposal, the New York Times said.
The proposal circulating among some committee members of both parties also would offer the option of lower-cost insurance that protects only against the costs of catastrophic illnesses to those who are 25 years old and younger, the Times said. In addition, the proposal would provide basic Medicaid coverage to millions of low-income people who now are ineligible for the program, but these benefits would be less-comprehensive than those of traditional Medicaid, the Times said.
BioLabs Pegasus Park Cultivates Life Science Ecosystem
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Today, Baucus will try to win support for the proposal from the three Republicans and two other Democrats on his finance committee with whom he has been deliberating for months, according to the Times. In the end, Baucus will need a majority of the committee’s 23 members, several of whom are resentful at being excluded from the deliberations thus far, the Times said.
Obama plans to meet at the White House today with top Democrats to coordinate a health reform strategy, the Times said. Administration officials declined to comment on the Baucus proposal or on the president’s speech to a joint session of Congress on Wednesday, the Times said. The speech is aimed in part to kick-start legislation to reform health care after the raucous town-hall meetings and misinformation that occurred during the congressional summer recess.
More stories worth a read:
- Obama’s Labor Day message: It’s time to ‘get this thing done’ (Dayton Daily News)
- President Obama says his critics lack healt-care answer (Washington Post)
- Deeply divided House Democrats return to work — and the same set of problems (Washington Post)
- Will safety net hospitals survive health reform? (Associated Press/Yahoo!)
- ’24 hours in the ER’ shows challenges of health system (USA Today)
- Michigan lawmakers debate health care plans (Detroit News)
- More insurance competition will not reduce costs (BNET Health Care)
- Roche and Glaxo team up to test rival swine flu drugs (Financial Times)
- Roche reshuffles management in biotech makeover (FierceBiotech)
- H1N1 swine flu: Vaccine faces setbacks (Chicago Tribune)
- Offit’s failure to disclose jeopardizes swine flu vaccine program (PRNewswire)
- Shortage of lupus patients challenges growing number of clinical studies (BusinessWire)
- Biotechs taking chances with Big Pharma earlier on(Dow Jones VentureWire Lifescience; paid subscription required)
- Later-stage valuations hold steady in 2Q after plunging in 1QÂ (Dow Jones VentureWire Lifescience; paid subscription required)
- Biogen makes unsolicited $356 million bid for Facet (FierceBiotech)
- University of Michigan researchers find gene that protects high-fat-diet mice from obesity (U of M News Service)
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
[Photo credit:Â Carolyn Bunce]
